Charles Slacik Biography and Net Worth

Director of QuidelOrtho


Charles P. Slacik is on the board of Quidel Corp. and Member of The Connecticut Society of Certified Public Accountants and Member of Financial Executives International - Orange County.

He previously occupied the position of Chief Financial Officer & Senior Vice President at C. R. Bard, Inc. (New Jersey), Chief Financial Officer & Executive Vice President for Actavis, Inc. and Chief Financial Officer & Senior Vice President at Beckman Coulter, Inc.

Mr. Slacik received an undergraduate degree from the University of Connecticut.

What is Charles P. Slacik's net worth?

The estimated net worth of Charles P. Slacik is at least $491,915.70 as of May 13th, 2021. Mr. Slacik owns 12,255 shares of QuidelOrtho stock worth more than $491,916 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Slacik may own. Learn More about Charles P. Slacik's net worth.

How do I contact Charles P. Slacik?

The corporate mailing address for Mr. Slacik and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on Charles P. Slacik's contact information.

Has Charles P. Slacik been buying or selling shares of QuidelOrtho?

Charles P. Slacik has not been actively trading shares of QuidelOrtho during the last ninety days. Most recently, Charles P. Slacik sold 1,000 shares of the business's stock in a transaction on Thursday, May 13th. The shares were sold at an average price of $113.26, for a transaction totalling $113,260.00. Following the completion of the sale, the director now directly owns 12,255 shares of the company's stock, valued at $1,388,001.30. Learn More on Charles P. Slacik's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), Joseph Busky (CFO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. During the last year, insiders at the sold shares 25 times. They sold a total of 10,521,742 shares worth more than $374,367,521.97. The most recent insider tranaction occured on November, 21st when Major Shareholder Carlyle Group Inc. sold 8,260,183 shares worth more than $291,667,061.73. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 11/21/2024.

Charles P. Slacik Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/13/2021Sell1,000$113.26$113,260.0012,255View SEC Filing Icon  
5/20/2019Sell1,000$55.19$55,190.008,703View SEC Filing Icon  
8/10/2018Sell1,000$68.28$68,280.007,820View SEC Filing Icon  
See Full Table

Charles P. Slacik Buying and Selling Activity at QuidelOrtho

This chart shows Charles P Slacik's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $40.14
Low: $37.49
High: $40.81

50 Day Range

MA: $41.38
Low: $36.18
High: $46.35

2 Week Range

Now: $40.14
Low: $29.74
High: $75.86

Volume

4,300,219 shs

Average Volume

921,692 shs

Market Capitalization

$2.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12